Why Is Sleep Devices Focused ProSomnus Stock Soaring Today?

ProSomnus Inc OSA announced the publication of a study by the Cureus Journal of Medical Science, highlighting the company's precision oral appliance therapy (OAT) devices for obstructive sleep apnea (OSA).

Key findings from the study include:

• 89% of all patients and 98.5% of mild to moderate OSA patients were treated to an apnea-hypopnea index (AHI) of fewer than ten events per hour.
• 80% of severe OSA patients were treated to an AHI of fewer than 20 events per hour, with a 50% improvement.
• After a minimum one-year follow-up period, 96% of patients continued using their precision OAT devices.

Also Read: EXCLUSIVE: Sleep Disorder Focused ProSomnus Raises $10M To Fuel Growth, Optimize Operations.

ProSomnus also announced additional clinical research highlighting the efficacy, decreased AHI incidents, and strong therapy adherence associated with the company's precision OAT devices:

• In a six-center study assessing the efficacy, repeatability and predictability of treating 58 moderate to severe OSA patients with ProSomnus EVO and a standard treatment protocol, participants' median obstructive AHI decreased from 20.54 to 3.9 events per hour, while 90% of patients experienced fewer than 15 events per hour. 
• In a study of 22 mild to moderate OSA patients, the ProSomnus® EVO was associated with a decreased AHI and strong compliance. After being treated with the EVO, patients' median AHI decreased from 21 to 4 events per hour, while 95% experienced fewer than ten events per hour. 
• Patients' compliance with the EVO, reported in the first three months of therapy, was 100%.

Price Action: OSA shares are up 73.50% at $1.09 on the last check Tuesday.